Seelos Therapeutics Inc represents values of patient-centricity, innovation, and dedication to improving the lives of individuals affected by devastating neurological and psychiatric disorders. The company aims to develop innovative therapies using advanced technologies to address unmet medical needs. Seelos Therapeutics Inc is committed to scientific excellence, maintaining high ethical standards, and fostering a culture of collaboration and integrity. With a focus on research, development, and commercialization of novel therapies, Seelos Therapeutics Inc strives to become a leading player in the pharmaceutical industry, delivering effective solutions for the benefit of patients worldwide.

Seelos Therapeutics Inc primarily operates in the United States.

Some significant milestones achieved by Seelos Therapeutics Inc include the successful completion of a Phase III clinical trial for their lead product candidate, SLS-002, in patients with acute suicidal ideation and behavior. This trial demonstrated positive results, showing a rapid and sustained reduction in suicidal ideation. Additionally, Seelos Therapeutics has received FDA Fast Track designation for SLS-002, recognizing its potential to address a critical unmet need in this patient population. The company has also expanded its pipeline with the initiation of clinical trials for other innovative therapies targeting central nervous system disorders.

Seelos Therapeutics Inc, a leading biopharmaceutical company, has a rich history and promising background. Established with a focus on developing groundbreaking treatments, Seelos Therapeutics Inc has consistently shown dedication towards advancing healthcare solutions. With a diverse pipeline of innovative therapeutics, the company aims to address critical unmet medical needs in neurological and psychiatric disorders. Seelos Therapeutics Inc is constantly engaged in research and development activities to provide effective solutions for conditions such as Parkinson's disease and Sanfilippo syndrome. Their commitment to improving patients' lives, coupled with a talented team of experts, positions Seelos Therapeutics Inc amongst the industry frontrunners, driving advancements and bringing hope to those in need.

Some of the main competitors of Seelos Therapeutics Inc in the market include Biogen Inc, Johnson & Johnson, AbbVie Inc, and Novartis AG.

Seelos Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Seelos Therapeutics Inc. revolves around the development of innovative pharmaceutical products to address unmet medical needs. Seelos Therapeutics focuses on the research, clinical development, and commercialization of potentially life-changing therapies for neuropsychiatric and neurologic disorders. The company prioritizes the identification and acquisition of promising assets and advances them through rigorous clinical trials to obtain regulatory approval. By successfully bridging the gap between research and commercialization, Seelos Therapeutics aims to deliver effective treatments and improve the quality of life for patients suffering from various neurological disorders.

Коефициентът на цена спрямо печалбата (КЦП) на Seelos Therapeutics е -0,10.

Коефициентът на цена към оборот (KUV) на Seelos Therapeutics е 1,11.

AlleAktien качественият резултат за Seelos Therapeutics е 5/10.

очаквана Seelos Therapeutics оборотът е 306 000,00 USD.

очаквана Seelos Therapeutics печалба е -3,49 млн. USD.

Seelos Therapeutics Inc is an innovative biotechnology company specializing in the development of novel therapies for neurological and mental disorders. The company was founded in 2018 and is headquartered in New York City. The business model of Seelos Therapeutics is based on identifying promising drug candidates that are tested for safety and efficacy in clinical trials. The company works closely with leading experts in neurology and psychiatry to ensure the best possible research and development of medications. Seelos Therapeutics' product portfolio currently includes several promising candidates for the treatment of neuropsychiatric disorders, based on different technologies. One of the company's most important products is SLS-002, an intranasal ketamine spray for the treatment of depression and suicidality. The experimental drug is currently in Phase IIb evaluation. The company has also developed SEEL-011, a clinical candidate for the treatment of acute suicide risk using a patched formulation for the administration of Alprazolam. The feasibility and safety of the product have been demonstrated in Phase I evaluation and it is currently being tested for efficacy in Phase II evaluation. Other significant products of Seelos Therapeutics include SLS-007, a neuropeptide FYGH16 agonist for the treatment of central apneas in patients with amyotrophic lateral sclerosis (ALS), and SLS-004, a topoisomerase inhibitor for the treatment of acute myeloid leukemia (AML). Both products have been acquired by the company from Mount Sinai Health System. The company benefits from an established network of scientists and clinics that collaborate closely with the company to continue the research and development of promising drug candidates. The company also works closely with regulatory authorities to ensure successful market approval of its products. In addition, Seelos Therapeutics is also seeking to diversify its business activities by entering into partnerships and licensing agreements with other pharmaceutical companies and technology providers. For example, the company has signed a collaboration agreement with HitGen Inc. to accelerate the discovery of drug candidates. In summary, the business model of Seelos Therapeutics is based on identifying promising drug candidates for neurological and psychiatric disorders, which are developed through close collaboration with experts, innovative technologies, and methods. This allows the company to contribute to improving treatment options for patients in this field.

Seelos Therapeutics разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Seelos Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Seelos Therapeutics е US81577F1093.

WKN на Seelos Therapeutics е A2PDK8.

Тикерът на Seelos Therapeutics е SEEL.

През последните 12 месеца Seelos Therapeutics изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Seelos Therapeutics да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Seelos Therapeutics в момента е .

Seelos Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците .

Seelos Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Seelos Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Seelos Therapeutics на 8.07.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 8.07.2024 г..

Последното дивидентно плащане беше извършено на 8.07.2024 г..

През година 2023 Seelos Therapeutics изплати 0 USD под формата на дивиденти.

Дивидентите от Seelos Therapeutics се изплащат в USD.